drugset / Trial / NCT02581137

Metformin Hydrochloride in Preventing Oral Cancer in Patients With an Oral Premalignant Lesion

NCT02581137 ↗

Phase 2 Active not recruiting 26 enrolled National Cancer Institute (NCI)
NaSingle-groupOpen-labelPrevention

Summary

This phase IIa trial studies how well metformin hydrochloride works in preventing oral cancer in patients with an oral premalignant lesion (oral leukoplakia or erythroplakia). Oral premalignant lesions look like red or whitish plaques or lesions in the mouth that do not rub off and can be associated with a higher risk of cancer. Metformin hydrochloride may help prevent oral cancer from forming in patients with an oral premalignant lesion.

Timeline

Start
2016-06-10
Primary completion
2017-10-12
Completion
2026-12-19

Drugs

EvaluationDrugModalityDoseRoute
Subject Metformin Small molecule 2000 mg Oral